SkinBioTherapeutics has appointed Stuart Ashman as an executive director, effective from April 18th.. Stuart will succeed Professor Cath O’Neill as CEO after a period of transition, which will enable him to gain an understanding of the science based company which is focused on skin health
| Manchester, UK – 23rd April 2019 –SkinBioTherapeutics has appointed Stuart Ashman as an executive director, effective from April 18th.. Stuart will succeed Professor Cath O’Neill as CEO after a period of transition, which will enable him to gain an understanding of the science based company which is focused on skin health. Cath will continue to drive the science and the ongoing commercial discussions she has initiated. Stuart brings over two decades of commercial healthcare experience, primarily in the medical devices industry, having held senior-level positions in a range of large public and smaller private companies. Since 2014, Stuart has served as CEO of Onbone Oy (“Onbone”), a Finnish private equity-backed medical device company. In this role, he successfully established a global sales force and distribution network and built a multimillion pound business with margins of 80%. Prior to that, Stuart was President/CEO of Andover Healthcare Inc., a US-based wound management manufacturer and President/CEO of TI Group, a UK-based medical/engineering company where he grew revenues from $19mill to $88mill per annum . Stuart also served as Senior VP, Global Sales & Strategic Marketing, BSN Medical (Biersdorf, Smith and Nephew) and was Director of Sales & Marketing at Smith & Nephew Plc, in its Woundcare, Casting & Bandaging division. In these roles, Stuart has extensive experience of both direct sales management across multiple geographies, business to business selling and involvement in M&A transactions. Martin Hunt, Non-Executive Chairman of SkinBioTherapeutics, commented,“ Stuart’s proven track record with both SMEs and larger public companies in Europe and the US will be essential in driving the company forward as we progress towards commercialisation of our first product. Cath, who has played a pivotal role as CEO, from discovering the technology, to founding the Company and leading it through the IPO will continue to lead the science.” Stuart, who served in the armed forces, has an MBA and a BSc in Business & Management. -ENDS- About SkinBioTherapeutics plc SkinBioTherapeutics is a life science company focused on skin health. The Company’s proprietary platform technology, SkinBiotix®, is based upon discoveries made by Dr. Catherine O’Neill and Professor Andrew McBain. SkinBioTherapeutics’ platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to the skin. The Company has shown that the SkinBiotix® platform can improve the barrier effect of skin models, protect skin models from infection and repair skin models. Proof of principle studies have shown that the SkinBiotix® platform has beneficial attributes applicable to each of these areas. SkinBioTherapeutics received seed funding from the Tech Transfer office of the University of Manchester for the discovery of SkinBiotix®. The platform was subsequently spun out of the University of Manchester in March 2016 and was funded by OptiBiotix (AIM: OPTI). The Company joined AIM in April 2017, concurrent with raising £4.5 million from a placing of new ordinary shares. The Company is based in Manchester, UK. For more information, visit www.skinbiotherapeutics.com. FOR MEDIA INFORMATION: |
